United Therapeutics Announces FDA Approval and Launch of Tyvaso(R) for the Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease

First and only approved therapy in the United States for patients with PH-ILD, a serious, life-threatening disease with potentially more than 30,000 patients in need FDA approval based on data from the INCREASE clinical trial PH-ILD is the second FDA... Biopharmaceuticals, FDA, Product Launch United Therapeutics, Tyvaso, treprostinil, pulmonary hypertension
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news